JP2007503202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503202A5 JP2007503202A5 JP2006521193A JP2006521193A JP2007503202A5 JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5 JP 2006521193 A JP2006521193 A JP 2006521193A JP 2006521193 A JP2006521193 A JP 2006521193A JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5
- Authority
- JP
- Japan
- Prior art keywords
- cytotoxic
- maytansine
- formula
- conjugate according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48844703P | 2003-07-21 | 2003-07-21 | |
| PCT/US2004/023340 WO2005009369A2 (en) | 2003-07-21 | 2004-07-21 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010262151A Division JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503202A JP2007503202A (ja) | 2007-02-22 |
| JP2007503202A5 true JP2007503202A5 (enExample) | 2009-03-12 |
Family
ID=34102763
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521193A Pending JP2007503202A (ja) | 2003-07-21 | 2004-07-21 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2010262151A Expired - Fee Related JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2014133794A Expired - Fee Related JP5997727B2 (ja) | 2003-07-21 | 2014-06-30 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2015237469A Expired - Fee Related JP6144749B2 (ja) | 2003-07-21 | 2015-12-04 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2017033672A Pending JP2017123857A (ja) | 2003-07-21 | 2017-02-24 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010262151A Expired - Fee Related JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2014133794A Expired - Fee Related JP5997727B2 (ja) | 2003-07-21 | 2014-06-30 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2015237469A Expired - Fee Related JP6144749B2 (ja) | 2003-07-21 | 2015-12-04 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2017033672A Pending JP2017123857A (ja) | 2003-07-21 | 2017-02-24 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050123549A1 (enExample) |
| EP (1) | EP1660513B9 (enExample) |
| JP (5) | JP2007503202A (enExample) |
| KR (5) | KR101263950B1 (enExample) |
| CN (3) | CN103554261B (enExample) |
| AT (1) | ATE496944T1 (enExample) |
| AU (1) | AU2004258955C1 (enExample) |
| BR (1) | BRPI0412879A8 (enExample) |
| CA (1) | CA2532430C (enExample) |
| CR (1) | CR8207A (enExample) |
| CY (1) | CY1111938T1 (enExample) |
| DE (1) | DE602004031239D1 (enExample) |
| DK (1) | DK1660513T5 (enExample) |
| EA (1) | EA014640B1 (enExample) |
| EC (1) | ECSP066294A (enExample) |
| ES (1) | ES2360403T3 (enExample) |
| HR (1) | HRP20110302T1 (enExample) |
| IL (2) | IL172982A (enExample) |
| MX (2) | MXPA06000830A (enExample) |
| NO (1) | NO339324B1 (enExample) |
| NZ (3) | NZ580855A (enExample) |
| PL (1) | PL1660513T3 (enExample) |
| PT (1) | PT1660513E (enExample) |
| SI (1) | SI1660513T1 (enExample) |
| WO (1) | WO2005009369A2 (enExample) |
| ZA (1) | ZA200600375B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US9539348B2 (en) | 2000-08-18 | 2017-01-10 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| EP3524611B1 (en) * | 2003-05-20 | 2020-12-30 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| WO2007024222A1 (en) * | 2005-08-22 | 2007-03-01 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| CN104804094A (zh) * | 2005-08-22 | 2015-07-29 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| AR069979A1 (es) * | 2007-12-26 | 2010-03-03 | Biotest Ag | Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados |
| RU2547939C2 (ru) * | 2007-12-26 | 2015-04-10 | Биотест Аг | Иммуноконъюгаты, направленные на cd138, и их применение |
| BRPI0821417A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
| DK2238168T3 (da) * | 2007-12-26 | 2014-08-25 | Biotest Ag | Midler, der er målrettet mod cd138 og anvendelser deraf |
| KR101892411B1 (ko) | 2008-04-30 | 2018-08-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| WO2010128087A2 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| RU2573994C2 (ru) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Антитела против cd20 и их применение |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| JP6162606B2 (ja) * | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス， インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
| US20130066055A1 (en) | 2011-04-21 | 2013-03-14 | Bayer Intellectual Property Gmbh | New binder-drug conjugates (adcs) and use thereof |
| CA2843771A1 (en) * | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| JP2012161321A (ja) * | 2012-03-30 | 2012-08-30 | Immunogen Inc | Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| PT2953977T (pt) | 2013-02-05 | 2018-01-29 | Sanofi Sa | Agente de imunoimagiologia para utilização com uma terapia de conjugado anticorpo-fármaco |
| JP2016515093A (ja) * | 2013-02-05 | 2016-05-26 | サノフイ | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 |
| BR112015022201B1 (pt) | 2013-03-15 | 2021-06-22 | Beckman Coulter, Inc | Método para projetar um painel de sonda para um citômetro de fluxo |
| AU2014298514A1 (en) * | 2013-08-02 | 2016-03-10 | Sanofi | Use of anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
| AU2014372833B2 (en) | 2013-12-23 | 2019-08-22 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
| WO2015138615A2 (en) * | 2014-03-12 | 2015-09-17 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| KR20240011258A (ko) | 2014-09-02 | 2024-01-25 | 이뮤노젠 아이엔씨 | 항체 약물 컨쥬게이트 조성물의 제형화 방법 |
| US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| PL3189056T3 (pl) | 2014-09-03 | 2020-11-02 | Immunogen, Inc. | Cytotoksyczne pochodne benzodiazepinowe |
| CN108025084B (zh) | 2015-06-22 | 2024-08-09 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| PT3380525T (pt) | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
| SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| WO2018114578A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
| EP3589328A1 (en) | 2017-02-28 | 2020-01-08 | Immunogen, Inc. | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| TW201839001A (zh) | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | 細胞毒性苯并二氮平衍生物及其綴合物 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| US11793885B2 (en) | 2017-12-28 | 2023-10-24 | Immunogen, Inc. | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders |
| CN120131907A (zh) | 2019-03-19 | 2025-06-13 | 瓦尔希伯伦私人肿瘤研究基金会 | 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| GEAP202416592A (en) * | 2022-02-03 | 2024-11-11 | Igm Biosciences Inc | Anti-cd38 binding molecules and uses thereof |
| KR20250089547A (ko) | 2022-10-25 | 2025-06-18 | 펩토믹, 에스.엘. | 암 치료를 위한 조합 요법 |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| WO2024251846A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69229477T2 (de) * | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MD1367C2 (ro) * | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| DE60032633T2 (de) * | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
| US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| AU2002340118B2 (en) * | 2001-10-04 | 2007-09-13 | Immunex Corporation | UL16 Binding protein 4 |
| EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
| US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US20030228305A1 (en) * | 2002-01-02 | 2003-12-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| NZ543498A (en) * | 2003-05-14 | 2007-06-29 | Immunogen Inc | A conjugate comprising an antibody chemically coupled to a maytansinoid |
-
2004
- 2004-07-21 MX MXPA06000830A patent/MXPA06000830A/es active IP Right Grant
- 2004-07-21 PT PT04778714T patent/PT1660513E/pt unknown
- 2004-07-21 DE DE602004031239T patent/DE602004031239D1/de not_active Expired - Lifetime
- 2004-07-21 SI SI200431646T patent/SI1660513T1/sl unknown
- 2004-07-21 ES ES04778714T patent/ES2360403T3/es not_active Expired - Lifetime
- 2004-07-21 AT AT04778714T patent/ATE496944T1/de active
- 2004-07-21 CA CA2532430A patent/CA2532430C/en not_active Expired - Fee Related
- 2004-07-21 CN CN201310444419.1A patent/CN103554261B/zh not_active Expired - Lifetime
- 2004-07-21 BR BRPI0412879A patent/BRPI0412879A8/pt not_active Application Discontinuation
- 2004-07-21 KR KR1020067001429A patent/KR101263950B1/ko not_active Expired - Fee Related
- 2004-07-21 CN CN201310020230.XA patent/CN103145844B/zh not_active Expired - Lifetime
- 2004-07-21 WO PCT/US2004/023340 patent/WO2005009369A2/en not_active Ceased
- 2004-07-21 JP JP2006521193A patent/JP2007503202A/ja active Pending
- 2004-07-21 NZ NZ580855A patent/NZ580855A/en not_active IP Right Cessation
- 2004-07-21 DK DK04778714.8T patent/DK1660513T5/da active
- 2004-07-21 NZ NZ612796A patent/NZ612796A/en not_active IP Right Cessation
- 2004-07-21 KR KR1020147008527A patent/KR101565721B1/ko not_active Expired - Fee Related
- 2004-07-21 KR KR1020127013238A patent/KR20120059657A/ko not_active Ceased
- 2004-07-21 AU AU2004258955A patent/AU2004258955C1/en not_active Ceased
- 2004-07-21 US US10/895,135 patent/US20050123549A1/en not_active Abandoned
- 2004-07-21 KR KR1020157031117A patent/KR101672664B1/ko not_active Expired - Fee Related
- 2004-07-21 PL PL04778714T patent/PL1660513T3/pl unknown
- 2004-07-21 KR KR1020127024607A patent/KR20120113811A/ko not_active Ceased
- 2004-07-21 CN CN2004800243313A patent/CN1922199B/zh not_active Expired - Lifetime
- 2004-07-21 EP EP04778714A patent/EP1660513B9/en not_active Expired - Lifetime
- 2004-07-21 NZ NZ598504A patent/NZ598504A/xx not_active IP Right Cessation
- 2004-07-21 HR HR20110302T patent/HRP20110302T1/hr unknown
- 2004-07-21 EA EA200600275A patent/EA014640B1/ru not_active IP Right Cessation
-
2006
- 2006-01-05 IL IL172982A patent/IL172982A/en active IP Right Grant
- 2006-01-13 ZA ZA2006/00375A patent/ZA200600375B/en unknown
- 2006-01-19 EC EC2006006294A patent/ECSP066294A/es unknown
- 2006-01-20 MX MX2011000245A patent/MX336469B/es unknown
- 2006-01-20 CR CR8207A patent/CR8207A/es unknown
- 2006-02-20 NO NO20060812A patent/NO339324B1/no not_active IP Right Cessation
-
2010
- 2010-11-25 JP JP2010262151A patent/JP5643619B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-21 CY CY20111100408T patent/CY1111938T1/el unknown
-
2014
- 2014-06-30 JP JP2014133794A patent/JP5997727B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-29 IL IL242336A patent/IL242336A/en active IP Right Grant
- 2015-12-04 JP JP2015237469A patent/JP6144749B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-24 JP JP2017033672A patent/JP2017123857A/ja active Pending